Amidst concerns about global growth and a stronger euro, the pan-European STOXX Europe 600 Index recently ended slightly lower, reflecting mixed performances across major European stock indexes. In such a market landscape, investors often seek opportunities that balance potential with financial resilience. Penny stocks—often representing smaller or newer companies—remain relevant for those willing to explore beyond established names, offering unique growth possibilities when backed by solid financials.
Top 10 Penny Stocks In Europe
| Name | Share Price | Market Cap | Rewards & Risks |
| Ariston Holding (BIT:ARIS) | €4.26 | €1.47B | ✅ 4 ⚠️ 2 View Analysis > |
| Maps (BIT:MAPS) | €3.37 | €44.76M | ✅ 4 ⚠️ 2 View Analysis > |
| Angler Gaming (NGM:ANGL) | SEK3.60 | SEK269.95M | ✅ 4 ⚠️ 2 View Analysis > |
| Angler Gaming (DB:0QM) | €0.37 | €247.45M | ✅ 2 ⚠️ 2 View Analysis > |
| Cellularline (BIT:CELL) | €3.14 | €66.23M | ✅ 4 ⚠️ 2 View Analysis > |
| Euroland Société anonyme (ENXTPA:ALERO) | €3.20 | €10.15M | ✅ 2 ⚠️ 5 View Analysis > |
| ForFarmers (ENXTAM:FFARM) | €4.475 | €395.52M | ✅ 4 ⚠️ 1 View Analysis > |
| High (ENXTPA:HCO) | €3.69 | €72.54M | ✅ 1 ⚠️ 4 View Analysis > |
| Deceuninck (ENXTBR:DECB) | €2.11 | €291.65M | ✅ 4 ⚠️ 1 View Analysis > |
| Netgem (ENXTPA:ALNTG) | €0.93 | €31.36M | ✅ 4 ⚠️ 2 View Analysis > |
Click here to see the full list of 330 stocks from our European Penny Stocks screener.
Below we spotlight a couple of our favorites from our exclusive screener.
Cellectis (ENXTPA:ALCLS)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Cellectis S.A. is a clinical stage biotechnological company focused on developing gene-editing products, including allogeneic chimeric antigen receptor T-cells for immuno-oncology and gene therapy candidates for other therapeutic areas, with a market cap of €175.03 million.
Operations: The company's revenue is derived entirely from its therapeutics segment, amounting to $63.44 million.
Market Cap: €175.03M
Cellectis S.A., a clinical-stage biotech firm, has shown significant revenue growth with US$18.19 million in Q2 2025 compared to US$9.5 million the previous year, though it remains unprofitable with a net loss of US$23.74 million for the quarter. Despite high volatility and negative return on equity, the company trades at a good value relative to peers and maintains more cash than debt, providing some financial stability. Recent strategic engagements at major healthcare conferences underscore its commitment to advancing its gene-editing technologies amid ongoing financial challenges and limited cash runway of less than one year if current trends persist.
- Click here and access our complete financial health analysis report to understand the dynamics of Cellectis.
- Gain insights into Cellectis' outlook and expected performance with our report on the company's earnings estimates.
SSH Communications Security Oyj (HLSE:SSH1V)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: SSH Communications Security Oyj is a cybersecurity company providing solutions for humans, systems, and networks across the Americas, Asia Pacific, Europe, the Middle East, and Africa with a market cap of €97.09 million.
Operations: The company generates revenue of €22.85 million from its software business.
Market Cap: €97.09M
SSH Communications Security Oyj, with a market cap of €97.09 million, is navigating the challenging landscape of penny stocks by focusing on innovation and strategic partnerships. Despite being unprofitable with increasing losses over five years and a negative return on equity, the company maintains a positive cash flow runway exceeding three years due to effective cash management. Recent developments include an expanded partnership with Portalify for secure communications and a strategic alliance with Leonardo S.p.A., enhancing its position in quantum-safe encryption solutions. However, short-term liabilities exceed assets, highlighting potential liquidity concerns amidst high stock volatility.
- Navigate through the intricacies of SSH Communications Security Oyj with our comprehensive balance sheet health report here.
- Review our growth performance report to gain insights into SSH Communications Security Oyj's future.
Viscom (XTRA:V6C)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Viscom SE develops, manufactures, and sells inspection systems for industrial production applications across Europe, the Americas, and Asia, with a market cap of €37.32 million.
Operations: The company's revenue is generated from various regions, including €28.85 million from Asia, €23.31 million from Germany, €12.39 million from the Americas, and €45.87 million from Europe excluding Germany.
Market Cap: €37.32M
Viscom SE, with a market cap of €37.32 million, operates within the penny stock realm by leveraging its inspection systems across multiple regions. Despite being unprofitable and experiencing increased losses over five years, the company has managed to reduce its net loss significantly year-over-year. The management team is seasoned, contributing to strategic stability amidst high share price volatility. While analysts forecast substantial earnings growth and potential stock price appreciation, Viscom's debt levels have risen over time. However, short-term assets exceed liabilities comfortably, providing some financial cushion as it targets revenue between €80-€90 million for 2025.
- Jump into the full analysis health report here for a deeper understanding of Viscom.
- Evaluate Viscom's prospects by accessing our earnings growth report.
Key Takeaways
- Reveal the 330 hidden gems among our European Penny Stocks screener with a single click here.
- Seeking Other Investments? We've found 18 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Cellectis might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com